ranQ
ranQ
ranQ
DirectoryIndustriesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The first Swiss company directory, built to boost AI visibility.

Product
  • Pricing
  • Directory
  • Industries
Company
  • About
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint742,806 companies indexed · Last updated: today
DirectoryIndustryPharmaceutical IndustryBaselTorqur AG
Torqur AG Logo
Verified· 2 sources

Torqur AG

Summary

About the company

Torqur AG is a clinical-stage biotechnology company focused on the discovery and development of PI3K/mTOR inhibitors for cancer therapy. The company is developing a portfolio of dual PI3K/mTOR compounds, including the candidate bimiralisib (PQR309) formulated for oral and topical use, and is conducting clinical trials in oncology and dermatology indications.

AI-generated
Offering

Products & services

Industry:Pharmaceutical Industry
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
✓ Offered5
Development of anti-cancer therapies
Platform for the discovery and efficient development of innovative anti-cancer therapies focused on the PI3K/mTOR signaling pathway and next-generation agents.
PI3K/mTOR inhibitors
Development of disease-specific mTOR and/or PI3K inhibitors with optimized pharmacokinetic and safety profiles for oncology and dermatology applications.
Bimiralisib (PQR309)
Lead candidate as a dual pan-PI3K and mTOR inhibitor for oral and topical use, investigated in multiple Phase 1/2 studies and additional clinical programs.
Clinical development in oncology and dermatology
Early clinical development and proof-of-concept studies for bimiralisib in various oncology and dermatology indications.
Pipeline development of next-generation PI3K/mTOR inhibitors
Building a portfolio with next-generation PI3K/mTOR inhibitors to expand therapeutic areas in oncology and beyond.

Knowledge

No knowledge articles yet

Once Torqur AG has claimed this profile, we'll publish editorial articles and case studies here together.

Get started
Comparisons

Torqur AG in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank Torqur AG by reviews, experience and specialisations.

Is this your company?

Claim the company profile of Torqur AG to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Lautengartenstrasse 6
4052 Basel
Opening hours
Mon
09:00 - 17:00
Tue
09:00 - 17:00
Wed
09:00 - 17:00
Thu
09:00 - 17:00
Fri
09:00 - 17:00
Sat
Closed
Sun
Closed

At a glance

Legal form
Corporation
UID
CHE-382.320.116
Founded
2021 · 5 years
Last commercial register change
December 22, 2025
Employees
21 to 50

Similar companies

TT
TOLREMO therapeutics AG
Basel
MP
Mepha Pharma AG
Basel
ST
Synendos Therapeutics AG
Basel
TT
TargImmune Therapeutics AG
Basel